Anti-Human KLRK1 Recombinant Antibody (KYK-2.0) (CAT#: TAB-521MZ)

Figure 1 is a graph that depicts the absorbance analysis of KYK-1.0 and KYK-2.0 Fab specificity using ELISA.

Shown is the binding of KYK-1.0 and KYK-2.0 Fab to a panel of proteins immobilized on an ELISA 96-well plate at 100 ng/well. TT11 Fab, which was selected from the same naïve human Fab library against tetanus toxoid, served as control. Error bars indicate mean±SEM (n=3).

Figure 2 is a series of flow cytometry analysis plots of the binding of KYK-2.0 IgG1 to human PBMC subpopulations.

Freshly isolated human PBMC were stained with APC-coupled mouse mAb to CD4, CD8, CD16 and with biotinylated KYK-2.0 IgG1 or TT11-IgG1 (negative control) followed by streptavidin-PE (y axes). PE-coupled mouse anti-human NKG2D mAb 149810 was used as positive control.

Figure 3 is a graph that depicts cytolytic activity of ex vivo expanded human NK cells by KYK-2.0 IgG1 measured as specific lysis based on 51Cr release.

Human K562 (top) or Daudi cells (bottom) were labeled with 51Cr and incubated with fresh human NK cells or ex vivo expanded human NK cells at an E:T ratio of 40:1 in the absence or presence of KYK-2.0 IgG1, TT11 IgG1 (negative control), and mouse anti-human NKG2D mAb 149810 (positive control). Error bars indicate mean±SD (n=3); the probability (p) is based on a paired one-tailed t-test.

Figure 4 is a series of flow cytometry analysis plots of the degranulation of human NK cells by immobilized KYK-2.0 IgG1.

Freshly isolated human PBMC were stimulated with IL-2 and then incubated with immobilized mAbs. Activation was detected with a mixture of FITC-coupled mouse anti-human CD107a and mouse anti-human CD107b mAbs. NK cells were detected with an APC-coupled mouse anti-human CD56 mAb. CD56+ CD107a/CD107b+ cells are gated (R3). Typical results for one healthy donor are shown. The percentage of degranulated NK cells (CD56+ CD107a/CD107b+) among total NK cells (CD56+) is shown in Table 2 of Example 4 herein for four different healthy donors.